Home > Boards > Free Zone > All Fundamentals > Special Purpose Acquisition Co (SPAC)

Trebia Acquisition Corp. Files for $375M IPO

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
MWM Member Profile
Member Level 
Followed By 913
Posts 128,631
Boards Moderated 24
Alias Born 03/31/06
160x600 placeholder
MWM Member Level  Monday, 06/01/20 08:27:44 PM
Re: None
Post # of 823 
Trebia Acquisition Corp. Files for $375M IPO
JUN 1, 2020 INTEL BY MATT CIANCI

Announces Cigna Preferred Contract Coverage for OVA1, Overa and Genetics Testing GlobeNewswire GlobeNewswireMarch 27, 2020 AUSTIN, Texas, March 27, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred agreement with Cigna. This contract includes OVA1, (Multivariate Index Assay, MIA) our ACOG endorsed ovarian cancer risk assessment test, as well as Overa and all genetic testing offered by ASPiRA. This agreement with Cigna will expand ASPiRA Labs contracted coverage by an additional 16 million lives. “We are excited to add one of the major national payers to the ASPiRA contracted payer network, allowing another 16 million lives to have access to all of ASPiRA’s testing as an in-network benefit,” said Valerie Palmieri, CEO of Vermillion. “This national agreement with Cigna is a major milestone for Vermillion and patients, as OVA1 continues on its trajectory to becoming the standard of care for ovarian cancer risk assessment. OVA1 is an FDA-cleared technology to assess ovarian cancer risk in women with pelvic masses inclusive of all ages, all stages. No comparable product exists on the market, with outstanding performance in premenopausal women, all cancer types and African American women.” About Vermillion, Inc. Vermillion, Inc. is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. Visit our website for more information about our products at www.vermillion.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist